Sergliflozin etabonate
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Sergliflozin_etabonate".

content
Sergliflozin etabonate
Systematic (IUPAC) name
2-[(4-methoxyphenyl)methyl]phenyl 6-O-(ethoxycarbonyl)-β-D-glucopyranoside
Identifiers
CAS number 408504-26-7
ATC code  ?
PubChem 9824918
Chemical data
Formula C23H28O9 
Mol. mass 448.463 g/mol
SMILES eMolecules & PubChem
Pharmacokinetic data
Bioavailability  ?
Metabolism  ?
Half life  ?
Excretion  ?
Therapeutic considerations
Pregnancy cat.

?
Legal status
Routes Oral

Sergliflozin etabonate (INN/USAN,12 codenamed GW869682X) is an investigational anti-diabetic drug being developed by GlaxoSmithKline.

Method of action

Sergliflozin inhibits subtype 2 of the sodium-glucose transport proteins (SGLT2), which is responsible for at least 90% of the glucose reabsorption in the kidney. Blocking this transporter causes blood glucose to be eliminated through the urine.34

References

  1. ^ World Health Organization (2008). "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 59". WHO Drug Information 22 (1): 66, http://whqlibdoc.who.int/druginfo/INN_2008_list59.pdf. 
  2. ^ "Statement on a nonproprietary name adopted by the USAN council: Sergliflozin etabonate". American Medical Association. Retrieved on 2008-08-10.
  3. ^ Katsuno K, Fujimori Y, Takemura Y, et al (January 2007). "Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level". J Pharmacol Exp Ther 320 (1): 323–30. doi:10.1124/jpet.106.110296. PMID 17050778, http://jpet.aspetjournals.org/cgi/content/full/320/1/323. 
  4. ^ Prous Science: Molecule of the Month November 2007


Tablets  This pharmacology-related article is a stub. You can help Wikipedia by expanding it.
v • d • e
Oral antidiabetic drugs and Insulin analogs (A10)
Insulin sensitizers
Secretagogues
GLP-1 analog
Alpha-glucosidase inhibitors
Amylin analog
Experimental
SGLT2 inhibitor
Dapagliflozin† · Remogliflozin† · Sergliflozin†
Insulin analogs
†Undergoing clinical trials. ‡ Withdrawn from market. §Development halted.
© jGames.co.uk 2007 (some content from Wikipedia under GDL ) !-- ValueClick Media 468x60 and 728x90 Banner CODE for jgames.co.uk -->
Your Ad Here